<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25214">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107014</url>
  </required_header>
  <id_info>
    <org_study_id>29911</org_study_id>
    <nct_id>NCT02107014</nct_id>
  </id_info>
  <brief_title>Low Dose Naltrexone (LDN) Immune Monitoring</brief_title>
  <acronym>LDN-IM</acronym>
  <official_title>Low Dose Naltrexone (LDN) Immune Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have found that low dose naltrexone (LDN) can substantially reduce pain associated with
      fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The
      purpose of this study is to determine if LDN lowers inflammatory markers in individuals with
      fibromyalgia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Change in average daily pain (0-100 Visual Analogue Scale) correlated with change in immune markers</measure>
    <time_frame>End of placebo compared to end of drug period. Total comparison period is 12 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in pain from placebo period to end of drug period correlated with change in immune markers from placebo to end of drug period</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Trial</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Naltrexone</intervention_name>
    <arm_group_label>Trial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females age 18-65

          -  Meets criteria for 1990 ACR criteria for fibromyalgia

          -  Able to receive venous blood draw twice a week for 16 weeks

          -  Sufficient symptom variability during baseline report

          -  Patient completes daily report during 2 week baseline period at least 80% completion
             rate.

        Exclusion Criteria:

          -  Opioid use

          -  Significant psychological comorbidity that in the discretion of the investigator
             compromises study integrity

          -  Location prohibits travel to Stanford

          -  Blood or clotting disorder

          -  Rheumatologic or autoimmune disease

          -  Acute infection

          -  Baseline blood ESR &gt;60, CRP greater than 3.0mg/L, positive rheumatoid factor, or
             positive ANA

          -  Use of blood thinning medication

          -  Pregnant or currently planning to become pregnant

          -  Current use of aspirin, ibuprofen, naproxen, or other confounding-anti-inflammatory
             medication as part of regular medication regimen.

          -  Known allergy to Naltrexone or Naloxone

          -  Currently participating in another treatment-based research study

          -  Self-reported inability to refrain from alcohol for the duration of the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jarred Younger, PhD</last_name>
    <phone>650-721-1988</phone>
    <email>youngerlab@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Parkitny, PhD</last_name>
      <phone>650-497-7671</phone>
      <email>youngerlab@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jarred Younger, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jarred Younger, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
